Bevacizumab-associated hypertension: Etiology, incidence, and management

Research output: Contribution to journalArticlepeer-review

2 Scopus citations


Bevacizumab (Avastin) is a recently developed monoclonal antibody, which targets the vascular endothelial growth factor signaling pathway, and is currently used in combination with cytotoxic agents as first-line or second-line therapy for patients with metastatic colon cancer. Hypertension is a known risk factor associated with the use of bevacizumab. In this report, we describe the incidence, etiology, and management of patients with this complication.

Original languageEnglish (US)
Pages (from-to)S22-S24
JournalAnti-Cancer Drugs
Issue numberSPEC. ISS. 2
StatePublished - May 2009


  • Avastin
  • Metastatic colon cancer
  • VEGF

ASJC Scopus subject areas

  • Oncology
  • Pharmacology
  • Pharmacology (medical)
  • Cancer Research


Dive into the research topics of 'Bevacizumab-associated hypertension: Etiology, incidence, and management'. Together they form a unique fingerprint.

Cite this